We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: clinical trial
MedXY News
EnglishTag

clinical trial

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Early Intervention in Pulmonary Arterial Hypertension: The Promise of Sotatercept in the First Year Post-Diagnosis
Cardiologyclinical trialpulmonary arterial hypertension

Early Intervention in Pulmonary Arterial Hypertension: The Promise of Sotatercept in the First Year Post-Diagnosis

By MedXY|Oct 25, 2025

This article reviews a phase 3 trial analyzing sotatercept’s efficacy and safety in newly diagnosed pulmonary arterial hypertension patients, highlighting its potential to reduce clinical worsening early in the disease course.

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial
newscervical cancerclinical trial

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial

By MedXY|Oct 25, 2025

The SENTIX trial shows that sentinel lymph node biopsy without full pelvic lymphadenectomy is safe in early-stage cervical cancer, potentially reducing surgical morbidity without compromising oncologic outcomes.

Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial
Internal Medicineclinical trialimmunotherapy

Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial

By MedXY|Oct 25, 2025

This article reviews a pivotal phase 3 trial demonstrating telitacicept’s efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.

Evaluating Atezolizumab Maintenance Therapy in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Insights from the IMvoke010 Trial
Oncologyatezolizumabclinical trial

Evaluating Atezolizumab Maintenance Therapy in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Insights from the IMvoke010 Trial

By MedXY|Oct 25, 2025

Atezolizumab maintenance therapy after multimodal definitive treatment failed to improve event-free or overall survival in high-risk LA SCCHN patients in the phase 3 IMvoke010 trial, highlighting challenges in immunotherapy for this setting

Cutting-Edge Treatment for EGFR-Mutated NSCLC: Sacituzumab Tirumotecan Shows Promising Survival Benefits
Oncologyclinical trialeGFR

Cutting-Edge Treatment for EGFR-Mutated NSCLC: Sacituzumab Tirumotecan Shows Promising Survival Benefits

By MedXY|Oct 24, 2025

A phase 3 trial demonstrates that sacituzumab tirumotecan significantly improves progression-free and overall survival in EGFR-mutated advanced NSCLC resistant to TKI therapy.

Breakthrough ADC-Based Combination Therapy Achieves Over 95% Disease Control in Advanced Urothelial Cancer
OncologyAntibody-drug conjugateclinical trial

Breakthrough ADC-Based Combination Therapy Achieves Over 95% Disease Control in Advanced Urothelial Cancer

By MedXY|Oct 24, 2025

Datroway combined with rilvegostomig demonstrates impressive tumor response and disease control in advanced urothelial carcinoma, heralding a new therapeutic option in first- and second-line settings.

新诊断的儿童免疫性血小板减少症中使用艾曲波帕：早期治疗策略的突破
newsclinical trialEltrombopag

新诊断的儿童免疫性血小板减少症中使用艾曲波帕：早期治疗策略的突破

By MedXY|Oct 24, 2025

这项随机试验表明，艾曲波帕显著改善了新诊断为ITP的儿童的持续血小板反应，提供了一种潜在的早期干预选择。

Eltrombopag in Newly Diagnosed Pediatric Immune Thrombocytopenia: A Breakthrough in Early Treatment Strategy
Hematology-Oncologyclinical trialEltrombopag

Eltrombopag in Newly Diagnosed Pediatric Immune Thrombocytopenia: A Breakthrough in Early Treatment Strategy

By MedXY|Oct 24, 2025

This randomized trial demonstrates that eltrombopag significantly improves sustained platelet response in children with newly diagnosed ITP, offering a potential early intervention option.

Oral Valiltramiprosate in APOEε4/ε4 Carriers with Early Alzheimer’s Disease: Insights from the Phase III APOLLOE4 Trial
NeurologyAlzheimer's diseaseAPOEε4

Oral Valiltramiprosate in APOEε4/ε4 Carriers with Early Alzheimer’s Disease: Insights from the Phase III APOLLOE4 Trial

By MedXY|Oct 21, 2025

This phase III trial evaluated oral valiltramiprosate in APOEε4/ε4 homozygotes with early Alzheimer’s, showing brain atrophy slowing but limited overall clinical benefit, with nominal improvements in mild cognitive impairment subgroup

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial
Diabetes & Endocrinologyclinical trialobesity

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

By MedXY|Oct 18, 2025

The STEP UP trial demonstrates that once-weekly semaglutide 7.2 mg significantly improves weight loss outcomes versus 2.4 mg and placebo in adults with obesity, with a manageable safety profile.

Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review
Diabetes & Endocrinologyclinical trialmetabolic syndrome

Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review

By MedXY|Oct 18, 2025

This phase 2a trial demonstrates that monlunabant induces significant weight loss across various doses in obese adults with metabolic syndrome, with dose-dependent adverse events highlighting the need for further safety evaluation.

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib
Nephrologyclinical trialimmunotherapy

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib

By MedXY|Oct 16, 2025

This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.

IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial
Diabetes & Endocrinologyclinical trialThyroid Eye Disease

IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial

By MedXY|Oct 15, 2025

The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.

Individualized Perioperative Blood Pressure Management in Major Abdominal Surgery: Insights from the IMPROVE-multi Trial
Anesthesiologyacute kidney injuryclinical trial

Individualized Perioperative Blood Pressure Management in Major Abdominal Surgery: Insights from the IMPROVE-multi Trial

By MedXY|Oct 13, 2025

The IMPROVE-multi randomized clinical trial found that tailoring perioperative blood pressure targets to individual preoperative nighttime MAP levels did not reduce postoperative organ injury or mortality compared to routine management in h

Simvastatin Fails to Slow Disability Progression in Secondary Progressive Multiple Sclerosis: Insights from the Phase 3 MS-STAT2 Trial
Neurologyclinical trialmultiple sclerosis

Simvastatin Fails to Slow Disability Progression in Secondary Progressive Multiple Sclerosis: Insights from the Phase 3 MS-STAT2 Trial

By MedXY|Jan 15, 2026

In a large phase 3 trial, simvastatin 80 mg daily did not reduce disability progression in secondary progressive multiple sclerosis, challenging prior phase 2 results and underscoring the complexity of neurodegeneration in SPMS.

Simplifying Ulcerative Colitis Treatment: Evaluating a Single 1600 mg 5-ASA Tablet Regimen in the EASI Trial
Gastroenterologyadherenceclinical trial

Simplifying Ulcerative Colitis Treatment: Evaluating a Single 1600 mg 5-ASA Tablet Regimen in the EASI Trial

By MedXY|Oct 9, 2025

The EASI trial compared a once-daily 1600 mg 5-ASA tablet with the conventional three 800 mg tablet regimen for ulcerative colitis, finding similar adherence and relapse rates, suggesting a feasible simpler alternative.

Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial
Clinical UpdatesBiliary tract cancerchemotherapy

Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial

By MedXY|Oct 6, 2025

A South Korean phase 3 trial found that adding polymeric micellar paclitaxel to gemcitabine and cisplatin did not improve survival for advanced biliary tract cancer, highlighting the challenges of intensified chemotherapy regimens.

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management
Diabetes & Endocrinologyclinical trialGLP-1 receptor agonist

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management

By MedXY|Oct 9, 2025

Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies

Long-Term Safety and Effectiveness of Personalized Adaptive Deep Brain Stimulation in Parkinson’s Disease
Clinical Updatesclinical trialneuromodulation

Long-Term Safety and Effectiveness of Personalized Adaptive Deep Brain Stimulation in Parkinson’s Disease

By MedXY|Oct 9, 2025

This international trial demonstrates that personalized adaptive deep brain stimulation (aDBS) is a safe, effective, and well-tolerated long-term therapy for Parkinson’s disease patients previously stable on continuous DBS.

Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials
newsclinical trialCOPD

Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials

By MedXY|Oct 9, 2025

Cytisinicline significantly improves smoking cessation rates and is well tolerated in smokers with self-reported COPD, supporting its use as an effective treatment option for this high-risk population.

Prev
5 / 10
1…34567…10
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities